Hikal net rises by 16%, thrust on pharma

Our Corporate Bureau
24 July 2002

Mumbai: Hikal Ltd has posted a 16-per cent growth in net profit at Rs 4.53 crore for the quarter ended 30 June 2002 as against Rs 3.92 crore in the corresponding quarter of the last year.

Hikals sales showed a 12-per cent rise as compared to the performance during the corresponding period last fiscal. Its sales during the quarter under review stood at Rs 27.08 crore as against Rs 24.25 crore registered during the Q1 of the last fiscal.

Hikals main thrust of business is in pharmaceuticals. It has already started constructing a new multi-product facility in Bangalore to manufacture active pharmaceutical ingredients (API) for the attractive US markets.

Hikal, a global growth company, is expanding its business relations internationally through collaborations with reputed corporations. In 2001, Hikal took over the pharmaceutical research centre and the API unit (bulk drug manufacturing) in Bangalore from Wintac.

The company has already made a mark for itself in the areas of crop protection chemicals, APIs and research and development.

Hikal is a leading global manufacturer of Thiabendazole (TBZ), a post-harvest fungicide. The company is also involved in custom synthesis and toll manufacture of pharmaceuticals, agrochemicals and intermediates. It has manufacturing facilities in Taloja, Mahad, Panoli and Bangalore. All the Hikal plants are ISO 9000-certified. Its Taloja and Panoli plants are ISO 14000-certified.